DiscoveryProbe™ FDA-approved Drug Library: Verifiable Evidence for High-Throughput Screening

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) comprises 2,320 bioactive compounds approved by major regulatory agencies, each supplied as a 10 mM solution in DMSO for reproducible screening (ApexBio). The library covers diverse pharmacological mechanisms, including receptor modulation and enzyme inhibition, supporting high-content and high-throughput screens (internal evidence). Peer-reviewed studies demonstrate its utility in identifying synergistic drug effects and repurposing candidates, as exemplified by ChaC1-based screens in hepatocellular carcinoma (Zheng et al. 2023). The compounds are compatible with automated workflows and are stable for up to 24 months at –80°C. This library is a validated platform for target identification, pathway mapping, and translational research across oncology and neurodegeneration.

Biological Rationale

Drug discovery research increasingly leverages high-throughput and high-content screening methods to accelerate identification of novel therapeutics. Clinically approved drug libraries provide pre-validated, structurally diverse compounds with known safety profiles. The DiscoveryProbe™ FDA-approved Drug Library contains 2,320 compounds approved by agencies such as the FDA, EMA, HMA, CFDA, and PMDA or listed in official pharmacopeias (product documentation). These agents act on a wide array of biological targets, including G-protein coupled receptors, ion channels, kinases, and metabolic enzymes. Modern disease models—especially in oncology and neurodegeneration—demand tools that can interrogate diverse mechanisms, facilitate drug repositioning, and identify new pharmacological targets. By using approved molecules, researchers can more rapidly advance hits to clinical development, reducing attrition due to unexpected toxicity or poor bioavailability (see also). This library directly addresses these translational gaps.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ FDA-approved Drug Library is curated to represent a spectrum of pharmacological activities:

• Receptor agonists and antagonists: e.g., metformin (AMPK modulator), doxorubicin (topoisomerase II inhibitor), atorvastatin (HMG-CoA reductase inhibitor).
• Enzyme inhibitors: Proteasome inhibitors such as bortezomib, used in ChaC1-mediated glutathione depletion screens (Zheng et al. 2023).
• Ion channel modulators: e.g., calcium channel blockers and antiarrhythmic agents.
• Signal pathway regulators: Compounds validated for roles in apoptosis, cell cycle, ER stress, and oxidative stress responses.

All compounds are supplied as 10 mM pre-dissolved solutions in DMSO, compatible with automated liquid handling and multi-format microplate systems (96-well, deep-well, 2D barcoded tubes). This formulation ensures reproducibility and minimal batch-to-batch variability. The stability profile is validated for 12 months at –20°C and up to 24 months at –80°C (ApexBio).

Evidence & Benchmarks

• ChaC1-based drug screenings using the FDA-approved drug library identified auranofin as a potent cell death inducer in glutathione-depleted hepatocellular carcinoma (HCC) cells (Zheng et al. 2023).
• Proteasome inhibitors (bortezomib, ixazomib, delanzomib) from the library induced endogenous ChaC1 expression in HCC cells in an ATF4-dependent manner (Zheng et al. 2023).
• Combination treatment with auranofin and proteasome inhibitors led to synergistic cell death, which could be blocked by N-acetyl-L-cysteine but not by necrostatin-1 or ferrostatin-1, indicating a specific, non-necroptotic mechanism (Zheng et al. 2023).
• Compounds in the DiscoveryProbe™ library have been benchmarked for mechanism-driven screening in cancer and neurodegenerative disease models, enabling robust, reproducible hit identification (LabPE article).
• The library is machine-readable and validated for integration with automated high-throughput workflows, supporting both target-based and phenotypic screening paradigms (Entinostat.net article).

Applications, Limits & Misconceptions

Applications:

• High-throughput screening (HTS) of clinically relevant, structurally diverse bioactive compounds.
• High-content screening (HCS) for mechanistic pathway elucidation in disease models.
• Drug repositioning: Rapid identification of new indications for existing drugs.
• Pharmacological target identification, including signaling pathway mapping and functional genomics.
• Translational research in oncology, neurodegeneration, and metabolic disease.

Limits:

• Library is restricted to compounds with prior clinical approval; novel chemical space is not represented.
• Does not address non-small molecule drugs (e.g., biologics, peptides).
• Activity in vitro does not guarantee in vivo efficacy; further pharmacokinetic and toxicology validation is required for repurposed hits.

Common Pitfalls or Misconceptions

• The library does not include experimental or preclinical-only compounds—only clinically approved small molecules.
• Hits identified in cell lines may not translate directly to animal models or clinical efficacy due to differences in metabolism or target expression.
• Compounds are supplied at 10 mM in DMSO; dilution and compatibility with assay buffers must be validated for each application.
• Some compounds may have off-target or pleiotropic effects; careful secondary screening is required to confirm mechanism.
• Not suitable for screening biologics, antibodies, or gene therapies.

This article provides a more detailed, evidence-grounded update on real-world screening outcomes and mechanistic benchmarks compared to the overview at DiscoveryProbe™ FDA-approved Drug Library: Enabling Mechanism-Guided Discovery, focusing specifically on recent ChaC1-based oncology screens. In contrast to the method summary at Atomic Evidence for High-Content Screening, this article highlights validated workflows and evidence from peer-reviewed studies.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is optimized for integration into automated and manual screening workflows:

• Supplied as pre-dissolved 10 mM solutions in DMSO, compatible with 96-well, deep-well, or 2D barcoded screw-top tube formats.
• Storage: Stable for 12 months at –20°C; 24 months at –80°C. Shipping on blue ice (evaluation samples) or at room temperature/blue ice for bulk orders.
• Each compound is annotated with regulatory approval status and known mechanism(s) of action.
• Machine-readable plate maps and compound metadata facilitate rapid deployment in LIMS and robotic systems.
• Recommended screening concentrations are typically in the 0.1–10 µM range, depending on target and assay sensitivity.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) provides a gold-standard, evidence-backed platform for high-throughput and high-content drug screening. Its use in ChaC1-based hepatocellular carcinoma studies exemplifies its capacity to identify novel synergistic drug combinations and support rapid drug repurposing (Zheng et al. 2023). The library’s robust annotation, stability, and machine compatibility make it an indispensable resource for mechanism-driven research in oncology, neurodegenerative disease, and beyond. For further details and ordering information, see the DiscoveryProbe™ FDA-approved Drug Library product page.